Bristol-myers Squibb Co. (BMY)

$41.2

-0.28

(-0.68%)

Market is closed - opens 7 PM, 17 Jun 2024
star icon

Bristol-Myers Squibb Co is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Insights on Bristol-myers Squibb Co.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 10.96B → 11.86B (in $), with an average increase of 3.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 5 quarters, 2.26B → -11.91B (in $), with an average decrease of 200.0% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 93.5% return, outperforming this stock by 129.8%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 293.0% return, outperforming this stock by 331.9%

Performance

  • $40.78
    $41.86
    $41.20
    downward going graph

    1.03%

    Downside

    Day's Volatility :2.58%

    Upside

    1.56%

    downward going graph
  • $39.91
    $63.65
    $41.20
    downward going graph

    3.13%

    Downside

    52 Weeks Volatility :37.3%

    Upside

    35.27%

    downward going graph

Returns

PeriodBristol-myers Squibb Co.Sector (Health Care)S&P500
3 Months
-20.14%
0.4%
6.1%
6 Months
-19.75%
8.7%
15.1%
1 Year
-37.73%
10.3%
22.7%
3 Years
-38.43%
17.0%
27.9%

Highlights

Market Capitalization
84.1B
Book Value
$8.14
Dividend Share
2.34
Dividend Yield
5.79%
Earnings Per Share (EPS)
-3.1
PEG Ratio
2.24
Wall Street Target Price
48.32
Profit Margin
-13.5%
Operating Margin TTM
19.25%
Return On Assets TTM
5.39%
Return On Equity TTM
-25.33%
Revenue TTM
45.5B
Revenue Per Share TTM
22.21
Quarterly Revenue Growth YOY
4.7%
Gross Profit TTM
36.4B
EBITDA
18.2B
Diluted Eps TTM
-3.1
Quarterly Earnings Growth YOY
-0.09
EPS Estimate Current Year
0.52
EPS Estimate Next Year
6.41
EPS Estimate Current Quarter
-4.44
EPS Estimate Next Quarter
1.75

Analyst Recommendation

Hold
    32%Buy
    64%Hold
    3%Sell
Based on 31 Wall street analysts offering stock ratings for Bristol-myers Squibb Co.(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
20
20
19
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 17.28%

Current $41.20
Target $48.32

Company Financials

FY18Y/Y Change
Revenue
22.6B
↑ 8.59%
Net Income
5.0B
↑ 391.76%
Net Profit Margin
21.95%
↑ 17.1%
FY19Y/Y Change
Revenue
26.1B
↑ 15.89%
Net Income
3.4B
↓ 30.55%
Net Profit Margin
13.15%
↓ 8.8%
FY20Y/Y Change
Revenue
42.5B
↑ 62.62%
Net Income
-9.0B
↓ 361.56%
Net Profit Margin
-21.16%
↓ 34.31%
FY21Y/Y Change
Revenue
46.4B
↑ 9.09%
Net Income
7.0B
↓ 177.75%
Net Profit Margin
15.08%
↑ 36.24%
FY22Y/Y Change
Revenue
46.2B
↓ 0.49%
Net Income
6.3B
↓ 9.54%
Net Profit Margin
13.71%
↓ 1.37%
FY23Y/Y Change
Revenue
45.0B
↓ 2.5%
Net Income
8.0B
↑ 26.84%
Net Profit Margin
17.83%
↑ 4.12%
Q4 FY22Q/Q Change
Revenue
11.4B
↑ 1.68%
Net Income
2.0B
↑ 25.9%
Net Profit Margin
17.73%
↑ 3.41%
Q1 FY23Q/Q Change
Revenue
11.3B
↓ 0.6%
Net Income
2.3B
↑ 11.87%
Net Profit Margin
19.95%
↑ 2.22%
Q2 FY23Q/Q Change
Revenue
11.2B
↓ 0.98%
Net Income
2.1B
↓ 8.36%
Net Profit Margin
18.47%
↓ 1.48%
Q3 FY23Q/Q Change
Revenue
11.0B
↓ 2.32%
Net Income
1.9B
↓ 6.99%
Net Profit Margin
17.58%
↓ 0.89%
Q4 FY23Q/Q Change
Revenue
11.5B
↑ 4.66%
Net Income
1.8B
↓ 8.61%
Net Profit Margin
15.35%
↓ 2.23%
Q1 FY24Q/Q Change
Revenue
11.9B
↑ 3.38%
Net Income
-11.9B
↓ 775.99%
Net Profit Margin
-100.39%
↓ 115.74%
FY18Y/Y Change
Total Assets
10.7B
↓ 68.23%
Total Liabilities
7.3B
↓ 66.14%
FY19Y/Y Change
Total Assets
129.9B
↑ 1119.1%
Total Liabilities
78.2B
↑ 964.72%
FY20Y/Y Change
Total Assets
118.5B
↓ 8.82%
Total Liabilities
80.6B
↑ 3.01%
FY21Y/Y Change
Total Assets
109.3B
↓ 7.74%
Total Liabilities
73.3B
↓ 9.05%
FY22Y/Y Change
Total Assets
96.8B
↓ 11.43%
Total Liabilities
65.7B
↓ 10.38%
FY23Y/Y Change
Total Assets
95.2B
↓ 1.72%
Total Liabilities
65.7B
↓ 0.04%
Q4 FY22Q/Q Change
Total Assets
96.8B
↓ 1.4%
Total Liabilities
65.7B
↑ 0.37%
Q1 FY23Q/Q Change
Total Assets
94.3B
↓ 2.62%
Total Liabilities
62.4B
↓ 5.03%
Q2 FY23Q/Q Change
Total Assets
93.5B
↓ 0.84%
Total Liabilities
61.5B
↓ 1.5%
Q3 FY23Q/Q Change
Total Assets
91.3B
↓ 2.38%
Total Liabilities
62.2B
↑ 1.21%
Q4 FY23Q/Q Change
Total Assets
95.2B
↑ 4.27%
Total Liabilities
65.7B
↑ 5.58%
Q1 FY24Q/Q Change
Total Assets
99.0B
↑ 4.07%
Total Liabilities
82.5B
↑ 25.59%
FY18Y/Y Change
Operating Cash Flow
5.9B
↑ 12.61%
Investing Cash Flow
-874.0M
↑ 1224.24%
Financing Cash Flow
-3.5B
↓ 13.29%
FY19Y/Y Change
Operating Cash Flow
8.1B
↑ 35.81%
Investing Cash Flow
-9.8B
↑ 1017.85%
Financing Cash Flow
7.6B
↓ 315.59%
FY20Y/Y Change
Operating Cash Flow
14.1B
↑ 74.19%
Investing Cash Flow
-10.9B
↑ 11.15%
Financing Cash Flow
-1.2B
↓ 115.1%
FY21Y/Y Change
Operating Cash Flow
16.2B
↑ 15.34%
Investing Cash Flow
-538.0M
↓ 95.05%
Financing Cash Flow
-16.2B
↑ 1309.56%
FY22Y/Y Change
Operating Cash Flow
13.1B
↓ 19.38%
Investing Cash Flow
-1.1B
↑ 97.4%
Financing Cash Flow
-17.0B
↑ 4.55%
FY23Y/Y Change
Operating Cash Flow
13.9B
↑ 6.08%
Investing Cash Flow
-2.3B
↑ 116.1%
Financing Cash Flow
-9.4B
↓ 44.49%
Q4 FY22Q/Q Change
Operating Cash Flow
3.3B
↓ 10.33%
Investing Cash Flow
1.2B
↓ 158.29%
Financing Cash Flow
-3.2B
↓ 28.55%
Q1 FY23Q/Q Change
Operating Cash Flow
3.0B
↓ 10.16%
Investing Cash Flow
-210.0M
↓ 117.31%
Financing Cash Flow
-3.1B
↓ 6.04%
Q2 FY23Q/Q Change
Operating Cash Flow
1.9B
↓ 36.46%
Investing Cash Flow
-329.0M
↑ 56.67%
Financing Cash Flow
-2.2B
↓ 28.75%
Q3 FY23Q/Q Change
Operating Cash Flow
4.8B
↑ 151.78%
Investing Cash Flow
-410.0M
↑ 24.62%
Financing Cash Flow
-5.2B
↑ 137.46%
Q4 FY23Q/Q Change
Operating Cash Flow
4.3B
↓ 10.5%
Investing Cash Flow
-1.3B
↑ 228.29%
Financing Cash Flow
967.0M
↓ 118.74%

Technicals Summary

Sell

Neutral

Buy

Bristol-myers Squibb Co. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
-6.6%
-19.75%
-37.73%
-38.43%
-14.54%
Eli Lilly And Company
Eli Lilly And Company
13.92%
51.52%
96.21%
297.92%
674.65%
Johnson & Johnson
Johnson & Johnson
-5.67%
-6.37%
-11.38%
-11.49%
4.37%
Merck & Co. Inc.
Merck & Co. Inc.
-1.07%
22.1%
18.44%
69.01%
55.44%
Abbvie Inc
Abbvie Inc
2.58%
9.89%
21.6%
45.93%
114.35%
Amgen Inc.
Amgen Inc.
-5.12%
8.4%
30.03%
24.64%
67.4%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
12.66
NA
2.24
0.52
-0.25
0.05
0.06
8.14
Eli Lilly And Company
Eli Lilly And Company
129.9
129.9
1.43
13.77
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
21.61
21.61
0.89
9.89
0.24
0.08
0.03
29.09
Merck & Co. Inc.
Merck & Co. Inc.
142.16
142.16
0.1
8.05
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
49.57
49.57
0.45
10.47
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
42.58
42.58
2.39
18.12
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bristol-myers Squibb Co.
Bristol-myers Squibb Co.
Hold
$84.1B
-14.54%
12.66
-13.5%
Eli Lilly And Company
Eli Lilly And Company
Buy
$839.5B
674.65%
129.9
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$350.1B
4.37%
21.61
44.92%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$327.7B
55.44%
142.16
3.76%
Abbvie Inc
Abbvie Inc
Buy
$294.1B
114.35%
49.57
11.02%
Amgen Inc.
Amgen Inc.
Buy
$160.1B
67.4%
42.58
12.74%

Institutional Holdings

  • Vanguard Group Inc

    9.18%
  • BlackRock Inc

    8.02%
  • State Street Corporation

    4.52%
  • JPMorgan Chase & Co

    4.38%
  • Capital Research & Mgmt Co - Division 3

    3.46%
  • Charles Schwab Investment Management Inc

    2.65%

Corporate Announcements

  • Bristol-myers Squibb Co. Dividends March,2024

    In the quarter ending March,2024. Bristol-myers Squibb Co. has declared dividend of $0.6

    Read More

Company Information

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Organization
Bristol-myers Squibb Co.
Employees
34100
CEO
Dr. Christopher S. Boerner Ph.D.
Industry
Health Technology

FAQs